Bioventus (BVS) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue grew 10.3% year-over-year to $151.2 million, with organic growth of 14% driven by double-digit gains in Pain Treatments and Surgical Solutions, marking the third consecutive quarter of double-digit organic growth.

• Adjusted EBITDA rose 22.4% to $34.5 million, reflecting strong revenue and margin expansion.

• Net loss from continuing operations was $32.1 million, impacted by a $31.9 million non-cash impairment charge and litigation settlement costs.

• Strategic decision to divest the Advanced Rehabilitation Business to focus on core operations and improve liquidity.

• Full-year 2024 guidance was raised, citing enhanced revenue growth and execution of strategic priorities.

Financial highlights

• Q2 2024 revenue reached $151.2 million, up 10.3% year-over-year; organic revenue (excluding wound business divestiture) grew 14%.

• Adjusted EBITDA was $34.5 million, a 22% increase year-over-year; adjusted EBITDA margin improved to 22.8%.

• Adjusted gross margin improved 180 basis points to 75.8%, while GAAP gross margin expanded to 68.5%.

• Adjusted operating income rose 12% to $31 million; adjusted net income increased 37% to $15 million; adjusted EPS was $0.19.

• Net loss per share from continuing operations was $0.37, compared to $0.06 last year.

Outlook and guidance

• 2024 net sales guidance raised to $557–$567 million, a $19.5 million increase at the midpoint.

• Full-year organic revenue growth expected to exceed 12%; adjusted EBITDA guidance increased to $104–$107 million.

• Adjusted EPS guidance raised to $0.36–$0.42, up $0.10 at the midpoint.

• Net leverage ratio expected to fall below 3x before end of 2025.

• Management expects current cash, cash equivalents, operating cash flows, and credit facility access to be sufficient for at least 12 months.